Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant platinum chemotherapy in locally advanced prostate cancer with DNA damage repair defects
ChiCTR2000033662Phase 2Completed
- Sponsor
- Renji Hospital
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and cisplatin in prostate adenocarcinoma, sponsored by Renji Hospital. Primary endpoints: Pathological remission rate and Adverse events. Started Jun 2020; status: completed.
02
Drugs
docetaxelcisplatin
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000033662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033662.